Amelanotic Choroidal Melanoma with Extraocular Extension in a 51 Year-Old Female: A Rare Case
Downloads
Introduction: Melanoma is a dangerous malignancy primarily involving the choroid, ciliary body, or iris. The most frequent primary intraocular malignant tumor is choroidal melanoma. The tumor most often affects Caucasians of Northern Europe ranging between the ages of 50 and 80. Most choroidal melanomas are pigmented, however, non-pigmented or mixed pigmented and non-pigmented forms can also happen. Compared with other amelanotic choroidal lesions, amelanotic choroidal melanoma showed markedly greater basal diameter, thickness, frequent connection with subretinal fluid, and ultrasonic hollowness. Extrascleral extension is currently detected in 10% to 28% of choroidal melanoma patients, and the mortality rate is much greater than in those without the extension. Case Presentation: We reported a rare case of extraocular extension in a 51-year-old female patient with amelanotic melanoma. The primary complaint was a painful and bleeding mass on her left eye that had developed two months prior to admission. On the conjunctiva of the left eye, there was a solid, palpable mass measuring 4 x 3.5 x 1 cm. It was red, well-defined, and had a hard, solid consistency. It was fixed at the base, had minimal bleeding, and pressed on her eyeball from the inferolateral direction. The cornea appears clear, and there is no light perception in visual acuity. The orbital focus computed tomography scan revealed an Enhancing solid mass containing a fat component. The mass was in the left intraocular, extending from intraconal to extraconal. Conclusions: Amelanotic melanoma with extraocular extension is a rare condition that can be difficult to detect due to its unclear clinical symptoms and wide range of possible causes. Patients and their families must be educated to receive the appropriate first therapy and prevent the illness from worsening. Melanoma management depends on several factors: tumor size, location, related characteristics, opposite eye status, systemic status, and patient preference. Orbital exenteration is one of the management options for choroidal melanoma with significant extraocular extension. By the time ocular treatment begins, the patient's survival may already be predetermined, and this realization could impact how uveal melanoma is treated in the years to come.
Singh AD, Turell ME, Topham AK. Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 2011;118:1881–1885. https://doi.org/10.1016/j.ophtha.2011.01.040.
Bellmann C, Lumbroso-Le Rouic L, Levy C, Plancher C, Dendale R, Sastre-Garau X, et al. Uveal melanoma: Management and outcome of patients with extraocular spread. British Journal of Ophthalmology 2010;94:569–574. https://doi.org/10.1136/bjo.2009.165423.
Welch RJ, Newman JH, Honig SE, Mayro EL, McGarrey M, Graf AE, et al. Choroidal amelanotic tumours: Clinical differentiation of benign from malignant lesions in 5586 cases. British Journal of Ophthalmology 2020;104:194–201. https://doi.org/10.1136/bjophthalmol-2018-313680.
Khurana N. Aggressive presentation of choroidal melanoma in a young female. Delhi Journal of Ophthalmology 2015;26. https://doi.org/10.7869/djo.155.
Shields CL, Manalac J, Das C, Ferguson K, Shields JA. Choroidal melanoma. Curr Opin Ophthalmol 2014;25:177–185. https://doi.org/10.1097/ICU.0000000000000041.
Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina 2012;32:1363–1372. https://doi.org/10.1097/IAE.0b013e31824d09a8.
Nalcaci S, Palamar M, Yaman B, Akalin T, Mentes J. Choroidal malignant melanoma with no extraocular extension presenting as orbital cellulitis. Orbit 2016;35:285–287. https://doi.org/10.1080/01676830.2016.1176216.
Lemaí®tre S, Zmuda M, Jacomet PV, Lévy-Gabriel C, Dendale R, Berges O, et al. Small choroidal melanoma revealed by a large extrascleral extension. Ocul Oncol Pathol 2017;3:240–246. https://doi.org/10.1159/000455870.
Finger PT. Choroidal melanoma. New York: Eye Cancer Center 2021. https://eyecancer.com/eye-cancer/conditions/choroidal-tumors/choroidal-melanoma/ (accessed August 18, 2021).
Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern M-H, et al. Uveal melanoma. Nat Rev Dis Primers 2020;6:24. https://doi.org/10.1038/s41572-020-0158-0.
Singh AD, Damato B, editors. Clinical Ophthalmic Oncology. Berlin, Heidelberg: Springer; 2014. https://doi.org/10.1007/978-3-642-40489-4.
Shields CL, Manalac J, Das C, Ferguson K, Shields JA. Choroidal melanoma: Clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol 2014;25:177–185. https://doi.org/10.1097/ICU.0000000000000041.
Sonda K, Mona R, Saloua Ben A, Jamel F. Invasive squamous cell carcinoma of the conjunctiva. Int J Immunother Cancer Res 2020:22–24. https://doi.org/10.17352/2455-8591.000026.
Kaliki S, Shields CL. Uveal melanoma: Relatively rare but deadly cancer. Eye 2017;31:241–257. https://doi.org/10.1038/eye.2016.275.
Copyright (c) 2024 Octarina Ervianti, Delfitri Lutfi
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Vision Science and Eye Health Journal by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The journal allows the author to hold the copyright of the article without restrictions.
The journal allows the author(s) to retain publishing rights without restrictions.
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Share-Alike (CC BY-SA).
The Creative Commons Attribution-Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violations.